LPCN News and Press, Lipocine Inc. From 09/26/22

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders PR Newswire Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial...

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference PR Newswire SALT LAKE CITY , Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment th...

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) PR Newswire FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine ...

Lipocine press release ( NASDAQ: LPCN ): Q2 GAAP EPS of -$0.04 in-line. Revenue of $0.5M beats by $0.24M . As of June 30, 2022, the company had $37.4 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $46.6 million at D...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 PR Newswire SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metaboli...

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment PR Newswire Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY , July 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovati...

Lipocine (NASDAQ:LPCN) on Tuesday said it had been granted two U.S. patents for its central nervous system and liver programs. LPCN stock +6% to $0.88 in premarket trading. The U.S. Patent and Trademark Office granted LPCN patent 11,337,987 for "Compositions and Methods for Treating...

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS PR Newswire SALT LAKE CITY , June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the...

LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE PR Newswire SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrin...

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results PR Newswire LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Obser...